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Population pharmacokinetics 
and dose optimization 
of vancomycin in neonates
Soon Min Lee1,4, Seungwon Yang2,4, Soyoung Kang3 & Min Jung Chang2,3* 
The pharmacokinetics of vancomycin vary among neonates, and we aimed to conduct population 
pharmacokinetic analysis to determine the optimal dosage of vancomycin in Korean neonates. From 
a retrospective chart review, neonates treated with vancomycin from 2008 to 2017 in a neonatal 
intensive care unit (NICU) were included. Vancomycin concentrations were collected based on 
therapeutic drug monitoring, and other patient characteristics were gathered through electronic 
medical records. We applied nonlinear mixed-effect modeling to build the population pharmacokinetic 
model. One- and two-compartment models with first-order elimination were evaluated as potential 
structural pharmacokinetic models. Allometric and isometric scaling was applied to standardize 
pharmacokinetic parameters for clearance and volume of distribution, respectively, using fixed 
powers (0.75 and 1, respectively, for clearance and volume). The predictive performance of the final 
model was developed, and dosing strategies were explored using Monte Carlo simulations with AUC 
0–24 targets 400–600. The patient cohort included 207 neonates, and 900 vancomycin concentrations 
were analyzed. Only 37.4% of the analyzed concentrations were within trough concentrations 
5–15 µg/mL. A one-compartment model with first-order elimination best described the vancomycin 
pharmacokinetics in neonates. Postmenstrual age (PMA) and creatinine clearance (CLcr) affected 
the clearance of vancomycin, and model evaluation confirmed the robustness of the final model. 
Population pharmacokinetic modeling and dose optimization of vancomycin in Korean neonates 
showed that vancomycin clearance was related to PMA and CLcr, as well as body weight. A higher 
dosage regimen than the typical recommendation is suggested. 
Neonates, especially premature infants, are susceptible to gram-positive  infections1. According to the Korean 
Neonatal Network, the overall incidence of sepsis among low-birth weight infants was 21%, with gram-positive 
organisms being the most prevalent organisms: coagulase-negative Staphylococcus is most common, followed by 
Staphylococcus aureus2. Methicillin-resistant S. aureus (MRSA) accounts for 80% of all isolated S. aureus cases 
in intensive care units and has become a threat to critically ill populations in  Korea3. Neonates with suspected 
sepsis typically receive vancomycin.
Neonates exhibit major and rapid physiological changes in drug distribution, metabolism, excretion, and 
absorption (for drugs after parenteral administration)4. More extensive inter- and intra-individual variability in 
pharmacokinetics has been described for neonates, compared to adults, and a larger variability in drug disposi-
tion and a poor relation between the dose administered and the concentration achieved in neonates has been 
recorded for most  drugs5,6.
Vancomycin, a glycopeptide antibiotic, has the potential to cause severe nephrotoxicity and ototoxicity. His-
torically, vancomycin dosing has been titrated to obtain serum trough concentrations of 10 to 15 mg/L for 
infections and 15 to 20 mg/L for severe infections, such as bacterial  meningitis7,8. Several proposed vancomycin 
dosing regimens are currently available for neonates; however, target trough concentrations are difficult to 
attain in clinical  practice9. Despite the widespread use of vancomycin and therapeutic drug monitoring in neo-
nates, controversy exists regarding optimal pharmacokinetics (PK)/pharmacodynamics (PD) targets, dosing, 
and  monitoring1. There is also evidence of correlations between serum vancomycin concentrations and clinical 
cure, microbiological cure, and nephrotoxicity in  neonates10,11.
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Although several population pharmacokinetic models of vancomycin exist, only a few individualized, model-
based dosing algorithms in neonates are  available9,12,13. Population PK modeling and simulation approaches 
allow us to characterize population averages, to assess the inter- and intra-subject variability of pharmacokinetic 
parameters, and to identify the optimal dosing of antibiotics. Accordingly, this study aimed to conduct a popula-
tion pharmacokinetic analysis to obtain pharmacokinetic data for vancomycin in Korean neonate infants and to 
develop an optimal vancomycin dosing strategy using model simulation.
Results
Patients. The demographic and clinical characteristics of the 207 neonates are described in Table 1. The 
median gestational age was 31.5 weeks; the median birth weight was 1.5 kg.
In total, 900 vancomycin concentrations were analyzed. Vancomycin treatment was administered at a median 
post-natal age (PNA) of 2.3 weeks and postmenstrual age (PMA) of 35.6 weeks. The dosage regimens admin-
istered to patients varied, with most patients receiving a dose of 10 mg/kg for 1 h every 8 or 12 h. Only 37.4% 
(337/900) were within the therapeutic range.
Pharmacokinetic modeling. The observed vancomycin concentration–time profiles were best described 
by a one-compartment model with first-order elimination. The model-derived pharmacokinetic parameters 
were CL and V. Interindividual variability was best explained by an exponential model that estimated CL and 
V; the model showed a correlation between total clearance (CL) and volume of distribution (V) [△ objective 
function value (OFV) = – 47.9]. Residual variability was best described by a combined additive and proportional 
model.





















Table 1.  Demographic and clinical characteristics of the study population. Data are presented as median 
(range). AST aspartate transaminase, ALT alanine aminotransferase.
Characteristic N = 207
Male, n (%) 103 (50)
Gestational age, weeks 31.5 (23.3–41.5)
 < 28 weeks, n (%) 68 (33)
28–31 weeks, n (%) 38 (18)
32–36 weeks, n (%) 34 (16)
 ≥ 37 weeks, n (%) 67 (32)
Birth weight, kg, mean ± SD 1.5 (0.5–5.4)
 < 1.5 kg, n (%) 75 (36)
 < 2.5 kg, n (%) 51 (25)
 ≥ 2.5 kg, n (%) 81 (39)
Apgar score at 1 min 4 (0–9)
Apgar score at 5 min 7 (0–10)
Post-natal age at examination, weeks 2.3 (0–16.4)
Postmenstrual age at examination, weeks 35.6 (24.0–48.4)
Body weight at examination, kg 1.8 (0.5–5.9)
Body length at examination, cm 41 (27–54)
Blood urea nitrogen, mg/dL 8.7 (1.3–76.4)
Serum creatinine, mg/dL 0.5 (0.2–2.6)
Creatinine clearance rate, mL/min/1.73  m2 50.3 (6.8–140.3)
Serum protein 4.9 (2.9–6.9)
Serum albumin level, g/L 3.2 (1.8–4.7)
AST, IU/L 25 (13–1838)
ALT, IU/L 10 (3–547)
C-reactive protein, mg/L 1.5 (0.1–123.3)
Vancomycin concentration, mcg/mL 18.5 (1.3–160.0)
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With the allometric size approach mentioned in the methods, PMA and CLcr on CL improved the population 
PK model of vancomycin in neonates (△OFV = –809.8). The final population pharmacokinetic model parameters 
for vancomycin and the bootstrap results are provided in Table 2.
Model diagnostics showed adequate goodness-of-fit for the final vancomycin PK model. There was good 
agreement between the observed and population-predicted/individual-predicted values for vancomycin serum 
concentrations (Fig. 1a,b). Figure 1c,d show that the conditional weighted residual vs. population-predicted 
values and time since last dose were equally distributed around zero and did not show any trends. The nonpara-
metric bootstrap analysis results are shown in Table 2. The prediction corrected (pc)-visual predictive check 
(VPC) results revealed the good predictive performance of the final population PK model for vancomycin 
(Fig. 2). After 1,000 simulations, the observed median, 2.5th, and 97.5th data were adequately captured by the 
corresponding simulation-based prediction intervals and 95% confidence intervals.
Simulation and dose optimization. The simulation of peak and trough concentrations at 96 h after the 
administration of vancomycin at 10, 15, and 20 mg/kg/dose every 6, 8, 12, and 24 h was performed based on 
target AUC 0–24 values ≥ 400. The optimized dose recommendations based on the simulated results are listed in 
Table 3. For example, if patients are PMA 32 weeks, with a CLcr of 40 mL/min/1.73  m2, a steady-state trough 
concentration of 15 mg/kg/dose q12h is recommended.
Discussion
Here, we aimed to determine the population PK of vancomycin in neonates and to optimize doses to better reflect 
clinical situations based on trough concentrations. This is the first study to evaluate dose optimization based on 
population PK modeling and to consider the clinical situations of limited samples for TDM and nephrotoxicity. 
The observed plasma vancomycin concentrations were well described; the recommended doses were predicted 
by simulation using the final population PK model. The study results were based on a one-compartment model, 
not a two-compartment model as in other studies 14,15. However, in support of our results, many studies have 
also shown that vancomycin PK in neonates is best described by a one-compartment  model13,16.
Here, a vancomycin 10 mg/kg/dose was administered according to PMA and PNA recommended by  Neofax7. 
Most patients were administered 10 mg/kg/dose q8h or q12h; lower or higher doses were administered based on 
the individual patients. With an increase in PMA or CLcr, vancomycin CL also increased; thus, allometric and 
isometric scaling using weights for both CL and V was applied to reflect neonatal characteristics. Our results 
were similar to those in previous studies showing that PMA and renal function are related to vancomycin PK 
parameters in  neonates12,13,16,17. Tseng et al. studied vancomycin PK in 76 neonates. They reported that PMA 
and SCr were related to vancomycin CL and performed allometric scaling using weights, although centering 
was additionally performed by dividing the weights by the median weight of the  neonates16. Li et al. also tried 
to build a covariate model in vancomycin population PK modeling, and allometric scaling by weights for CL 
and V was also performed. Therein, SCr was inversely related to vancomycin  CL13. As vancomycin is primarily 
excreted by the kidneys, kidney maturation is crucial for vancomycin dose determination. Accordingly, Rhodin 
et al. studied factors correlated with human renal function maturation and found that PMA is more strongly 
related to renal function maturation than  PNA17, which other have also reported 18–21. In our study, the power 
model best explained the relationship between CL and PMA. The Hill equation was proposed by previous stud-
ies to describe the relationship between CL and  PMA22,23. We also tried a sigmoidal model when describing 
maturation; however, because of the high value of variability and the limited range of PMA, we could not select 
Table 2.  Final population pharmacokinetics model parameters for vancomycin in neonates. a 95% CI 
estimated from 1000 resampled data sets using the final population (993 successful run). TVCL typical value 
of clearance (L/h), TVV typical value of volume of distribution (L), CLcr creatinine clearance (calculated by 
the Schwartz equation), PMA postmenstrual age, WT body weight, ωCL interindividual variability of clearance, 
ωv interindividual variability of volume of distribution, σproportional proportional residual error, σadditive additive 
residual error.






















θ1 2.09 (3%) 2.07 (1.94, 2.21)
θ2 0.795 (26%) 0.817 (0.396, 1.241)
θ3 0.741 (6%) 0.739 (0.641, 0.820)
θ4 45.6 (5%) 45.7 (41.6, 50.6)
Interindividual variability (ω)
ωCL 0.123 (26%) [21%] 0.130 (0.068, 0.217)
ωV 0.260 (25%) [35%] 0.296 (0.190, 0.425)
Residual variability (σ)
σproportional (%CV) 58.3% (8%) 58.6 (53.7, 63.8)
σadditive (mg/L) 2.015 (18%) 2.001(1.560, 2.296)
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that model as a final model. Also, the maturation of renal function was reported to reach about 62 weeks PMA 
24 but the range of PMAs of our study were 24.0–48.4 weeks. Therefore, this is one of the causes why the result of 
our study could not explain the sigmoidal model. Anderson et al. compared linear, exponential, and sigmoidal 
models on PMA, and they reported that a sigmoidal model best described the correlation between PMA and 
CL. However, before 50 weeks, they showed near linear  correlations25. Other studies also used power model to 
describe the age-effect of vancomycin population PKs in neonates instead of sigmoidal  model16,26,27. Therefore, 
based on the definition of neonates within 4 weeks after birth, a sigmoidal model might not show the best fit.
In contrast to previous findings, we found that CLcr is more relevant to vancomycin CL than  SCr12,13,16. SCr 
cannot reflect renal function directly because CLcr is also affected by age and weight. However, vancomycin PK 
parameters in neonates were usually adjusted by allometric scaling of weight: this might be why previous stud-
ies reported SCr to be related to vancomycin CL rather than CLcr. Here, we calculated CLcr using the Schwartz 
 equation28, which better reflects the clinical situation of newborns.
There are numerous approaches to determining the adequate dosage regimen of vancomycin in neonates. To 
reflect PD and PK, area-under-the-curve concentrations versus time to the minimum inhibitory concentrations 
(AUC: MIC) can be used. Currently, AUC 24/MIC ≥ 400 for MRSA infections provides sufficient  treatment16,29,30 
Figure 1.  Goodness-of-fit plots of the final population pharmacokinetics (PK) model for vancomycin. 
Observed vancomycin concentrations vs. (a) population-predicted concentrations and (b) individual-predicted 
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Tseng et al. reported that there is a positive relationship between AUC 24 and trough concentrations at a steady 
state  (Css,trough)  (r2 = 0.74) and that target trough concentrations 10‒14.9 μg/mL could achieve AUC 24/MIC > 400 
to ensure the efficacy and minimize nephrotoxicity and ototoxicity in  neonates16. Frymoyer et al. reported that 
trough concentrations around 10 mg/L can achieve AUC 0-24/MIC ≥  40031. Another study suggested that  Css,trough 
5–15 μg/mL could satisfy AUC 0-24/MIC ≥ 400 with less  toxicity12. However, AUC-guided dosing uses the MIC 
of S. aureus, and vancomycin MIC in neonates can be more variable. A MIC of 1 mg/L is typically used for the 
AUC-guided dosing of vancomycin, and steady-state trough concentrations are used to predict the efficacy and 
safety of  vancomycin32–34. As there is an increase in dose recommendation in neonates based on AUC-guided 
dosing, we also simulated target AUC 0–24 values ≥ 400 when MIC ≤ 1. The recommended dose optimization was 
slightly higher than Neofax. We suggest a therapeutic range for vancomycin  Css,trough of 5–15 μg/mL, as this 
range was highly predictive of AUC 0-24/MIC ≥  40012. Also, another study reported that  Css,trough 15–20 μg/mL had 
higher nephrotoxicity in  neonates16. A lower target than that of adults could be adequate for neonates, different 
from  Neofax7. For example, neonates with PMA of 36 weeks and PNA of 10 days with bacteremia by MRSA and 
with CLcr 50 mL/min/1.73  m2, our model suggests 15 mg/kg q12h, whereas Neofax suggests 10 mg/kg q12h.
Although the final model in this study showed robustness, there were some limitations. This is a retrospective 
observational study, and only peak and trough concentrations were sampled for TDM. However, it is challenging 
to perform multiple tests on neonates, and 900 samples is considered substantial.
Conclusion
This is the first study, to our knowledge, on vancomycin population PK modeling and dose optimization in a large 
number of Korean neonates. PMA and CLcr were related to vancomycin CL. Based on a  Css,trough of 5–15 μg/mL, 
a higher dosage regimen that that currently employed is recommended. A future long-term study is necessary 
to confirm the efficacy and safety of the newly recommended dosage regimen.
Figure 2.  Prediction-corrected visual predictive check for vancomycin. A thousand simulations were 
performed. Prediction-corrected observed concentrations are shown as open circles. The middle solid, lower 
dashed, and upper dashed lines represent the median, 2.5th, and 97.5th percentiles for the observed data, 
respectively. The shaded areas represent a 95% confidence interval for a simulated predicted median, 2.5th, and 
97.5th percentiles constructed from 1000 simulated datasets of individuals from the original dataset.
Table 3.  Dose recommendations for vancomycin in neonates. CLcr creatinine clearance, PMA postmenstrual 
age.
Dose (mg/kg) PMA (weeks)
CLcr (mL/min/1.73  m2)  < 24 24–27 28–31 32–35 36–39 40–43 44 ≤ 
 < 15 10 q24h 10–15 q24h 15 q24h
15–30 10 q24h 15 q24h 15 q24h 10 q12h 10–15 q12h 10 q8h
30–60 10 q12h 10 q8–12 h 15 q8–12 h 15 q8h
60–90 10 q8–12 h 10 q8h 15 q8–12 h 15 q8h 15–20 q8h 20 q8–12 h 20 q8h
90 ≤ 15 q12h 15–20 q12h 20 q12h 20 q8–12 h 20 q8h 25 q8h
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Materials and methods
Study design and patient eligibility. The data of neonates admitted to the Gangnam Severance Hos-
pital neonatal intensive care unit (NICU) from January 2008 to April 2017 who were treated with vancomycin 
for more than 24 h and had at least one steady-state plasma concentration measurement were retrospectively 
collected. Neonates were excluded if they developed acute kidney injury, including urine output < 1 mL/kg/h or 
serum creatinine ≥ 1.5 mg/dL, before the initiation of vancomycin administration. In total, 900 vancomycin con-
centrations from 207 neonates were included. The study protocol was approved by the institutional review board 
of Gangnam Severance Hospital (No. 3–2019-0206), Seoul, Korea, and the manuscript followed STROBE state-
ment. The need for informed consent was waived by the institutional review board because the data were ret-
rospectively collected. All methods were performed in accordance with the relevant guidelines and regulations.
Data collection. All data were collected from electronic medical records. Patient characteristics included 
date of birth, sex, weight at the time of birth, weight at the time closest to vancomycin initiation, height at the 
time of birth, gestational age, post-natal age (PNA), postmenstrual age (PMA), type of delivery, APGAR 1 min 
of age, APGAR 5 min of age, blood urea nitrogen, serum creatinine (SCr), creatinine clearance (CLcr) calculated 
using the Schwartz equation [CLcr (mL/min/1.73  m2) = [length (cm) × k]/Scr (k = 0.45 for infants 1 to 52 weeks 
old)]28, protein, albumin, aspartate transaminase (AST), alanine aminotransferase (ALT), and c-reactive pro-
tein (CRP). Vancomycin dosing and plasma level information were as follows: the date of starting vancomycin 
treatment, vancomycin dosage, peak plasma concentrations of vancomycin, and trough plasma concentrations 
of vancomycin. The vancomycin dosages administered to neonates followed the Neofax  recommendations7. 
According to Neofax, the dosing interval of 10 mg/kg/dose vancomycin should be determined by PMA and 
PNA. The peak vancomycin concentration was sampled 1 h after stopping vancomycin administration; trough 
concentrations were measured 0.5 h before the next dose. When there was more than one laboratory result or 
none on the same day as the plasma concentration sampling, the closest results were used in the analysis.
Serum vancomycin concentrations were analyzed via the chemiluminescent microparticle immunoassay 
(CMIA) (Abbott ARCHITECTi, Abbott Laboratories, Abbott Park, IL, USA). This method has a coefficient of 
variation of less than 10% for between-day as well as within-run imprecision. The lower limit of detection (LLOD) 
was 2.0 μg/mL and the lower limit of quantification (LLOQ) was 3.0 μg/mL. SCr concentrations were measured 
by kinetic Jaffe (compensated method) traceable to the IDMS reference method using AU5800 analyzer (Beck-
man coulter, Inc., Brea, CA, the USA). A coefficient variation was less than 3.0%, and the analytical measurement 
range (AMR) was 0.06 – 25.0 mg/dL. In case of BQL values, we treated them as observed values of extrapolation.
Population pharmacokinetic modeling. For the analysis of vancomycin population pharmacokinetic 
parameters, nonlinear mixed-effect modeling was performed using NONMEM ver. 7.3 (Icon Development 
Solutions, Ellicott City, MD, USA) in conjunction with Perl Speaks NONMEM (PsN ver. 4.4.0), Pirana (ver. 
2.9.7), and Xpose (ver. 4.0) contained in the R software package (ver. 3.5.0; http://www.r-proje ct.org). The popu-
lation analysis was conducted using the first-order conditional estimation method (FOCE) with ε–η interaction 
(FOCE INTER). One- and two-compartment models with first-order elimination were evaluated as potential 
structural pharmacokinetic models. The fixed-effect parameters were total clearance (CL) and volume of distri-
bution (V) for the one-compartment model, and total CL, central V (V1), peripheral V (V2), and inter-com-
partmental CL (Q) for the two-compartment model. Possible correlations among the interindividual variability 
for pharmacokinetic parameters in the model were assessed by the OMEGA BLOCK functionality. Allometric 
scaling was applied to CL and isometric scaling was applied to V to standardize the pharmacokinetic parameters. 
The final allometric model was as follows:
where CL is the clearance in the ith individual with body weight WTi; θCL is the typical CL value in a standard-
ized adult (70 kg); and θv is the typical V in a standardized adult (70 kg). Interindividual variability in the PK 
parameters was analyzed using exponential and power models. Covariance between interindividual variability 
was estimated using a variance–covariance matrix. Residual variability was attempted using additive, propor-
tional, and combined models.
Covariates were investigated for the population modeling using linear, proportional, power, and exponential 
functions. Almost all patient characteristics were tried as covariates in the modeling process. When objective 
function value was decreased by at least 3.84 (χ2-test, P < 0.05) from the structural model during the forward 
selection, the covariate was included in the model. All covariates that met the criteria were added to develop the 
full model. Then, during backward elimination, any covariate with an increase of at least 6.64 (χ2-test, P < 0.01) 
was kept in the model. The categorical covariates tested were as follows: sex (where female = 1, male = 0), and 
types of delivery (where NsvD = 0, Csec = 1). The continuous covariates tested were body weight, blood urea 
nitrogen, SCr, protein, albumin, neutrophil, AST, ALT, CRP, WBC, height, PMA, PNA, CLcr, and gestational age.
Model validation. Model validation was performed via three methods: graphical diagnostics using a good-
ness-of-fit plot, bootstrapping, and a pc-VPC. Individual observed vs. individual-predicted values and condi-
tional weighted residual vs. time or population-predicted values or individual-predicted values were plotted 
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using R for NONMEM. Bootstrap datasets were repeated 1,000 times using the final model; the pc-VPC was 
performed as a diagnostic plot.
Simulation. Monte Carlo simulation was performed to predict vancomycin concentrations from the differ-
ent dosing regimens to determine dose optimization for neonates. As PMA and CLcr were shown to be related to 
the population PK parameters of vancomycin in neonates, the simulation of vancomycin doses of 10 mg/kg q6h 
to q24h, 15 mg/kg q6h to q24h, and 20 mg/kg q6h to q24h were used to predict the vancomycin peak and trough 
concentrations according to PMA 28, 32, 36, 40, and 44 weeks and CLcr 30, 60, and 90 mL/min/1.73  m2. based 
on targeted efficacy reaching 400 ≤ AUC 0-24 ≤ 600 when MIC assumed to be 1 mg/L as the update of therapeutic 
monitoring of vancomycin guideline of the American Society of Health-System  Pharmacists12,28,35–37. Different 
from the conventional target of probability of target attainment (PTA) with 90% or higher when determining 
the PK/PD target of  antibiotics25, the PTA of vancomycin based on the AUC/MIC ≥ 400 target was reported to be 
much lower which was only 49% of the standard dose of 1000 mg q12h in case of MRSA  pathogens38. The target 
PTA of 400 ≤ AUC 0-24 ≤ 600 was set to be higher than 30%. To reduce the confusion, the PTAs of AUC 0-24 ≥ 400 
was also calculated with the target ≥ 90%. If more than one regimen is recommended in the same situation, dos-
age of the lowest daily dose and more frequent dosing with lower peak concentrations among the same daily 
dose is chosen to reduce the toxicity in pediatrics (Suppl. Information).
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